McCarthy Pumtiwitt C, Sharyan Abeer, Sheikhi Moghaddam Laleh
Department of Chemistry, Morgan State University, Baltimore, MD 21251, USA.
Vaccines (Basel). 2018 Feb 25;6(1):12. doi: 10.3390/vaccines6010012.
causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the pathogen. Immunization strategies have been effective at helping to decrease the global incidence of meningococcal meningitis. Researchers continue to enhance these efforts through discovery of new antigen targets that may lead to a broadly protective vaccine and development of new methods of homogenous vaccine production. This review describes current meningococcal vaccines and discusses some recent research discoveries that may transform vaccine development against in the future.
导致大多数细菌性脑膜炎病例。脑膜炎球菌性脑膜炎对全球发达国家和发展中国家都是一项公共卫生负担。有多种疫苗(基于多糖的、糖结合物的、基于蛋白质的和联合结合疫苗)被批准用于针对该病原体六个致病血清群中的五个。免疫策略在帮助降低脑膜炎球菌性脑膜炎的全球发病率方面已见成效。研究人员继续通过发现可能导致一种具有广泛保护作用的疫苗的新抗原靶点以及开发新的均一疫苗生产方法来加强这些努力。本综述描述了当前的脑膜炎球菌疫苗,并讨论了一些近期的研究发现,这些发现可能在未来改变针对[原文此处可能遗漏了具体疾病名称]的疫苗研发。